

The Editor,
World Journal of Clinical Cases

Re: The emerging role of biosimilars in the clinical care of inflammatory bowel disease patients

Dear Sir/Madam

Attached, please find the revised manuscript based on the reviewers' comments.

We hope that your readership will enjoy reading it and will benefit from it. We like to take this opportunity to thank the reviewers and editorial staff for their time and patience. Please let us know with any questions.

Regards

Salim Surani, MD

Reviewers Comments

I am honored to learn about the emerging role of biosimilars in the clinical care of IBD patients through this manuscript. With the global increase in IBD incidence, traditional drugs can no longer meet the standard treatment pursued by IBD. The advent of the era of biologics, especially anti-TNF- α , offers first-line treatment options. However, inevitable problems ensued, such as the loss of response of biologics, the increase in hospitalization rates, the financial burden of patients and psychological stress. Compared with the original research drug, biosimilars are highly similar in clinical behavior and product quality, whether they can be safe and effective alternative, popularized and used in clinical practice, the content discussed in this article has a certain practical significance. One suggestion is to highlight the advantages of biosimilars in the market competition. From a small level, it is to reduce the burden of patient care. On a large level, not only to make the pharmaceutical industry the fittest, but also to improve the use of NHS funds. In the future, we look forward to a safe and effective conclusion from large sample studies. It is hoped that through this article, biosimilars will be understood and publicized by doctors and patients, recognized and supported by insurance companies and government policies. The above is my personal opinion, if it is helpful to you, please adopt it

Response to the reviewers' comments

We appreciate the positive response from the reviewers. We do agree that biologics can long way to go in improving patient care and cost. In addition, it also studies are needed so it can be marketed as equitable and safe. We have incorporated those valuable points in the revised manuscript.

We have addressed

1. nocebo-effect
2. non-medical switch
3. use or mandatory use (tender systems) around the globe
4. exposures and market shares of biosimilar sales worldwide
5. practical conclusion for the clinician
6. biologics vs biosimilars

Reviewer Comments

This is a very basic review on technical processes and approvals of the biosimilars worldwide. Authors did not make a thorough effort to update us on most recent data, exposures and market shares of biosimilar sales worldwide, neither on the use or mandatory use (tender systems) around the globe, non-medical switch, nocebo effect etc. Most of the data highlighted are textbook style, the authors are clearly not expert in the field of

biologics/biosimilars in IBD and did not try to read and digest the available literature, thus the paper lacks novelty and practical conclusion for the clinicians. It is complete rewriting and restructuring that the paper needs.

Response to the reviewers' comments

We appreciate the reviewer's candid feedback. We do agree that this is very basic info. We did intend to provide the very basic info for the clinicians who are in the private practice and many non-GI physicians about the basic knowledge, availability, challenges, and advantages of the biosimilars, especially when it pertains to the inflammatory bowel disease. We do realize it is basic, but with this mini review we intended to provide a wide range of non-experts who are encountered with this clinical condition. We indeed appreciate the reviewer's vigilance in this regard.

Round 2

Response to the reviewers' comments

Dear Editor and Reviewers,

Thank you for your letter and comments on our manuscript, All comments are valuable and very helpful for revising and improving our manuscript, with important guiding significance to our studies.

We appreciate your positive comments and will try our best to further improve.